Press Release: Novartis: Sandoz introduces -2-

referred to in Novartis AG's current Form 20-F on file with the U.S. Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

References

1. Act4Biosimilars data on file (IQVIA MIDAS 2022).

2. Generics and Biosimilars Initiative. Biosimilars approved in Columbia.

Available from:

https://www.gabionline.net/biosimilars/general/biosimilars-approved-in-colombia [Accessed

May 2023]

3. Generics and Biosimilars Initiative. Biosimilars approved in Ecuador.

Available from:

https://gabionline.net/biosimilars/general/biosimilars-approved-in-Ecuador [Accessed

May 2023]

4. IQVIA. The Global Use of Medicines 2023. Available from:

https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicines-2023 [Accessed

May 2023]

5. European Medicines Agency and European Commission. Biosimilars in the EU:

information guide for healthcare professionals. 2019. Available

from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-infor

mati [Accessed May 2023].

# # #

About Sandoz

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world's leading and most valued generics company. Our broad portfolio of high-quality medicines covers all major therapeutic areas.

Sandoz on social media:

LinkedIn: https://www.linkedin.com/company/sandoz

Twitter: https://twitter.com/sandoz_global

Facebook: https://www.facebook.com/sandozglobal

Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor

# # #

Sandoz Global Communications

North

Central America

Michelle

Joerg Allgaeuer +49 171 8384838 Bauman +1 973-714-8043

Novartis Media Relations

E-mail: media.relations@novartis.com

North

Central America

Julie

Richard Jarvis +41 79 584 2326 Masow +1 862 579 8456

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line:

E-mail: investor.relations@novartis.com +41 61 324 7944

North

Central America

Sloan

Samir Shah +41 61 324 7944 Simpson +1 862 345 4440

Parag

Nicole Zinsli-Somm +41 61 324 3809 Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

June 15, 2023 01:15 ET (05:15 GMT)